Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624.

Published: 11th February 2013

Authors: Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S et al. et al.

Conclusion

This was a dose ranging study over eight weeks in 194 adults with moderate to severe colitis. A clinical response was more likely in patients who had the highest dose of the drug (15mg): 78 per cent versus 42 per cent with placebo; P<0.001.

Pubmed Link

Your comments

0 Comments